Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

Glenmark Pharmaceuticals said that the United States’ Food and Drug Administration (FDA) has concluded inspection of its manufacturing facility in Monroe, North Carolina.

Glenmark Pharmaceuticals said that the United States’ Food and Drug Administration (FDA) has concluded inspection of its manufacturing facility in Monroe, North Carolina. In an exchange filing, the company stated that the authorities conducted a Good Manufacturing Practice inspection at the facility between June 9-17.

Outcome of Inspection

Glenmark said that the FDA has issued a Form 483 upon the conclusion of its inspection at the manufacturing facility. The federal agency reported five observations in its report; however, the company said that there was no observation on data integrity, and all five observations were procedural in nature.

Glenmark stated that it will work with the Food and Drug Administration to address the observations by the agency. Furthermore, the company will respond to the FDA within a stipulated timeline.

Glenmark gets DCGI approval for cancer medicine

Earlier on June 9, Glenmark Pharmaceuticals received approval from the Drugs Controller General of India (DCGI) for Zanubrutinib, an oncology medicine. The medicine developed by US-based pharmaceutical company, BeOne Medicines, will be marketed by Glenmark under the brand name BRUKINSA.

The cancer medicine launched by Glenmark is known for its high response rate and lower cardiac event rate. According to Glenmark, BRUKINSA has a 1.9 percent serious cardiac event rate against the industry average of 7.7 percent serious cardiac event rate.

Glenmark’s share price

In the past month, Glenmark Pharmaceuticals’ stock has gained 15.40 percent . On Wednesday, Glenmark’s share was up by 0.42 percent at Rs 1,660 per share, by 1 PM.

Related Posts

  • Pharma
  • July 22, 2025
  • 149 views
DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

  • Pharma
  • July 16, 2025
  • 576 views
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug